Dementia is defined as a marked decline in cognitive function that is severe enough to affect social and occupational functioning.[@B1] The most common form of dementia is Alzheimer's disease, although many other conditions can cause dementia, including vascular dementia, Frontotemporal dementia (FTD), dementia with Lewy bodies, Parkinson's with dementia, and mixed dementia. Other less common disorders can also cause symptoms of dementias.[@B2]

At the end of 2010, there were 35.6 million people with dementia globally; 58% of whom were in middle-income countries. Dementia is projected to rapidly increase in the near future, by nearly 63% (relative to 2010 levels; i.e. to 65.7 million cases) in 2030 and by 71% (relative to 2010 levels; i.e. to 115.4 million cases) in 2050.[@B3] Dementia is therefore a growing global health concern, especially in low- and middle-income countries (LMIC) where there are major gaps in the availability of services. In Latin America, population ageing further adds to poor socioeconomic conditions in producing a critical scenario.[@B4]

Early identification of cognitive impairment can allow for timely intervention, thereby slowing down the progression of the disease. This can be especially beneficial in cases where the treatment does not modify the natural course of the disease.[@B5] Thus, the need for further research on early diagnosis of Alzheimer's disease, as well as on identifying the root cause of neurodegeneration and cognitive impairment, has been stressed in various studies as a means of prevention and control of disease progression globally.[@B6] ^,^ [@B7]

A study reported that generalists detect \<40% of patients with cognitive impairment, with failure rates proving highest in preclinical and prodromal stages than in patients with established dementia (56% versus 19%).[@B8] In this context, access to brief cognitive tests (BCTs) is essential to increase detection in outpatient consultations, whether as a screening test or to confirm a diagnosis in persons suspected of having cognitive impairment.[@B9] ^-^ [@B11]

One of the main drivers behind this study was to inform the medical community of existing validated BCTs for cognitive impairment. Understanding which BCTs have been validated would also help to identify existing research gaps and hence the research needs which might be prioritized in the future.

The study objective was to create a systematic map to identify and describe the properties of BCTs in Peru.

METHODS
=======

Study design
------------

We conducted a systematic mapping review of scientific articles on BCTs published in indexed journals based on a protocol that addressed the overarching objective of the study with the following research questions:

*RQ1. What are the BCTs validated in Peruvian populations according to scientific literature in both English and Spanish from inception to 2018?RQ2. What type of research is being conducted on BCTs in relation to screening and diagnosis for cognitive impairment (e.g. methodology, type of disorder, age, sex, education)?*

The properties of BCTs are: 1) ease of use, simplicity and short administration time (no more than 5-10 minutes for primary care doctors and specialists, respectively) and training; 2) objective evaluation, unequivocal (free of complex instructions) and straightforward assessment (without the need for additional instruments); 3) user-friendly and ecologically friendly (does not generate rejection in the individual being evaluated; 4) validated within the context in which it will be applied (independent of personal , sociodemographic, ethnic, or cultural characteristics); and 5) flexible to be adapted for use in other contexts.[@B12]

For the purpose of this study, the following BCTs were considered: 1) *Addenbrooke's Cognitive Examination* (ACE);[@B13] Eurotest[@B14] and its South-American versions as the Peruvian monetary test[@B15] or Chilean monetary test;[@B16] *Executive Battery 25* (EB25) and its abbreviated version AEB12;[@B17] *Free and Cued Selective Reminding Test* (FCSRT);[@B18] *Frontal Assessment Battery* (FAB);[@B19] *INECO Frontal Screening* (IFS);[@B20] *Memory Alteration Test* (M\@T);[@B21] *Memory Impairment Screen* (MIS);[@B22] *Memory, Fluency, and Orientation* (MEFO);[@B23] *Mini-Mental State Examination* (MMSE);[@B24] *Montreal Cognitive Assessment* (MoCA);[@B25] Clock Drawing Test (CDT);[@B26] and *Test Your Memory* (TYM).[@B27]

Data collection
---------------

The following databases were queried: Web of Science (primarily including MEDLINE and SciELO Citation Index), Scopus, MEDLINE, Excerpta Medica dataBASE (EMBASE), and Virtual Health Library (including LILACS, IBECS, CUMECS, BINACIS, PERNAL and MINSA). We used a broad set of search terms as follows: (*root "Peru"*) AND (complete and abbreviated search terms of each of the BCTs considered in this study) OR ("cognitive impairment" OR "cognitive decline" OR "dementia"). The latter terms were used in order to avoid excluding studies that evaluated different BCTs to those identified *a priori*. No temporal limitations were applied.

### Search process

The following search string was used on each of the reference databases. A total of 883 articles were obtained. Search results were put into an electronic database and duplicate articles eliminated. The remaining articles were reviewed by two independent researchers - a neurologist specialized in cognitive disorders (NC) and an epidemiologist specialized in systematic reviews (EHP), through the screening of title, abstract, and keywords.

At this point, the same two researchers filtered the 17 references, independently screening them for the full content of each paper. A final set of 15 references were produced and included in the study.

The following data were collected: a) study subjects (population, participant eligibility criteria, sample and comparison group); b) methodology (study design type); c) diagnostic procedures (ruling out other causes of cognitive impairment, tests, procedures and diagnostic criteria utilized; and d) BCT performance according to comparison groups (cut-off points, area under the ROC curve, sensitivity, specificity, % correctly classified, probability coefficient, predictive values, Cronbach's alpha, and Pearson's coefficient).

The *Pfeffer Functional Activities Questionnaire* (PFAQ) was also included for evaluating functioning and for the screening of dementia.[@B28] ^,^ [@B29]

Statistical analysis
--------------------

All studies selected and relevant information extracted was put into a database and further analyzed using STATA version 15. With the goal of comparing BCT performance, we utilized the area under the receiving operating characteristic (ROC) curve (AUC).

Ethical aspects
---------------

The protocol was approved by the ethics committee of the Instituto de Medicina Tropical "Daniel Alcides Carrión" of the Universidad Nacional Mayor de San Marcos under approval number CIEI-2018-020.

RESULTS
=======

Study selection
---------------

The search resulted in the retrieval of 883 articles, of which 436 duplicates were removed. A further 432 were excluded based on screening of the title and abstract. A total of 15 eligible articles were reviewed using the full-text version of the papers. Of these, five were subsequently excluded (two for insufficient information and three that were not focused on evaluating psychometric test performance). A total of 10 studies were thus selected for inclusion in the systematic mapping \[[Figure 1](#f1){ref-type="fig"}\]. These studies assessed only seven BCTs, namely, the MMSE, ACE, CDT-Mv, FAB, IFS, M\@T, and the Peruvian monetary test (PMT).

Figure 1Flowchart of study selection process

Study sample characteristics
----------------------------

Of the total studies included, two were secondary analyses from databases produced for other studies with different objectives. The studies included involved clinical samples from outpatient settings, where all but two were conducted using community-based residential samples[@B39] or in elderly day care centers, all of which were located in the capital city of Lima. Differential diagnosis included dementia, dementia of the Alzheimer type (DAT), frontotemporal dementia (FTD), Parkinson's disease dementia (PPD), mild cognitive impairment (MCI), and depression ([Table 1](#t1){ref-type="table"}).

###### General study characteristics.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                                                                          Study participants          Study group                                        Control group                                             Intergroup homogeneity
  ----------------------------------------------------------------------------------------------- --------------------------- -------------------------------------------------- --------------------------------------------------------- -------------------------------------------
  Oscanoa T, 2004[@B48]                                                                           Patients                    AD (31)                                            No AD (31)                                                Yes: Age and education\
                                                                                                                                                                                                                                           No: Sex[\*\*](#TFN4){ref-type="table-fn"}

  Custodio N, 2011[@B49]                                                                          Patients                    Dementia (103)                                     Negative controls (107)                                   Yes: Age and sex\
                                                                                                                                                                                                                                           No: Education

  Custodio N, 2012[@B50]                                                                          Patients Healthy subjects   DAT (40)\                                          Healthy                                                   Yes: Sex and education\
                                                                                                                              FTD (18)                                                                                                     No: Age

  Herrera-Pérez E, 2013^[†](#TFN1){ref-type="table-fn"}^ [@B51]                                   Patients Healthy subjects   Dementia (102): DAT (53), FTD (26), and PDD (23)   Healthy (70)\                                             Yes: Sex and education\
                                                                                                                                                                                 Depression (21)                                           No: Age

  Custodio N, 2014[@B52]                                                                          Patients                    DAT (90)\                                          Negative controls (180)[\*](#TFN3){ref-type="table-fn"}   Yes: Sex and education\
                                                                                                                              MCI (45)                                                                                                     No: Age

  Custodio N, 2015[@B53]                                                                          Patients Healthy subjects   bvFTD (28)                                         Healthy (20)                                              Yes: Age, sex and education

  Oscanoa T, 2016[@B15]                                                                           Sick Patients\              Dementia (42)                                      Without dementia (42)                                     Yes: Age, sex and education
                                                                                                  Healthy subjects                                                                                                                         

  Custodio N, 2016 \[A\][@B54]                                                                    Patients Healthy subjects   DAT (35)\                                          Healthy (48)                                              Yes: Age, sex and education\
                                                                                                                              FTD (34)                                                                                                     

  Custodio N, 2016 \[B\]^[†](#TFN1){ref-type="table-fn"}[‡](#TFN2){ref-type="table-fn"}^ [@B55]   General population          Dementia (103)                                     Negative controls (107)                                   Not evaluated

  Custodio N, 2017^[‡](#TFN2){ref-type="table-fn"}^ [@B56]                                        General population          early DAT (81)\                                    Negative controls (121)                                   Yes: Sex and education\
                                                                                                                              aMCI (45)                                                                                                    No: Age
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

secondary analysis studies;

community-based sample;

subjects recruited in non-neurological consultations;

based on calculations made by authors for the purpose of this study; AD: Alzheimer\'s disease; MCI: mild cognitive impairment; aMCI: amnestic mild cognitive impairment; DAT: dementia of the Alzheimer type; PDD: Parkinson\'s disease dementia; FTD: frontotemporal dementia; bvFTD: behavioral variant frontotemporal dementia; negative controls: subjects with negative results after applying diagnostic protocol used to identify study subjects.

We characterized studies in terms of the type of controls: 1) healthy participants; 2) participants who did not have the study disease; and 3) participants that had the study disease ruled-out (negative controls). We evaluated whether the comparison groups within each study were "comparable" in relation to basic criteria of sociodemographic variables ("intergroup homogeneity"). Results revealed that some study groups were not "comparable" in terms of age (four studies), sex (one study), and educational level (one study). However, for three studies, the comparison groups were comparable for all of these sociodemographic variables ([Table 1](#t1){ref-type="table"}).

Eligibility criteria common to the included studies were: age (particularly \>60 years of age), years of education received, the absence of disorders that could affect performance in executing the psychometric tests applied in each of the studies, sensory disorders (vision and hearing) or non-sensory disorders (motor or physical). Only one study included as exclusion criteria use of medications that affect cognitive performance (analgesic opioids, decongestants, anti-spasmodics, anticholinergics, antidepressants, antiarrhythmics, antipsychotics, antiemetics, anxiolytics, and valproate) ([Table 2](#t2){ref-type="table"}).

###### Study eligibility criteria.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                        Oscanoa\                                            Custodio\   Custodio\   Herrera-\    Custodio 2014   Custodio\   Oscanoa\   Custodio\    Custodio\    Custodio\   
                                                        2004                                                2011        2012        Pérez 2013                   2015        2016       2016 \[A\]   2016 \[B\]   2017        
  ----------------------------------------------------- --------------------------------------------------- ----------- ----------- ------------ --------------- ----------- ---------- ------------ ------------ ----------- ---
  Age (years)                                           ≥ 60                                                \> 65       \> 65       \> 55        \> 60           ≥ 50        ≥ 60       \> 60        \> 60        \> 60       

  Education (years)                                     ≥ 1                                                 ≥ 1         ≥ 4         ≥ 6          ≥ 6             ≥ 4         NR         ≥ 4          ≥= 0         ≥ 4         

  Language                                              NR                                                  Spanish     Spanish     Spanish      Spanish         Spanish     NR         Spanish      Spanish      Spanish     

  Lack of:                                              Visual impairment[\*](#TFN5){ref-type="table-fn"}   ✓           ✓           ✓            ✓               ✓           ✓          ✓            ✓            ✓           ✓

  Auditory impairment[\*](#TFN5){ref-type="table-fn"}   NR                                                  ✓           ✓           ✓            ✓               ✓           ✓          ✓            ✓            ✓           

  Motor impairment                                      hands[\*\*](#TFN6){ref-type="table-fn"}             NR          NR          NR           NR              NR          NR         NR           NR           NR          

  Physical impairment[\*](#TFN5){ref-type="table-fn"}   NR                                                  NR          ✓           ✓            ✓               ✓           NR         ✓            ✓            ✓           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

affects ability to conduct the evaluation;

impedes writing or reading tasks;

ü: reported. NR: not reported; NS: reported, but not specified.

With regard to the diagnostic protocols applied in each of the studies included, the presence of ruling out potential causes for secondary cognitive impairment was reviewed, revealing the Beck's Depression Inventory as the main tool used to rule out depression. Similarly, study protocols for carrying out laboratory tests, neuroimaging, and specialized evaluations were reviewed. One of the studies failed to report information on these data tests. Serological testing for syphilis and ELISA-HIV was also included. Likewise, a standardized neuropsychological battery included the *Rey Auditory Verbal Learning Test*, *Logical Memory Subtest* of the revised *Wechsler Memory Scale*, *Trail Making Test* A and B, the *Rey-Osterrieth Complex Figure test,* the *Boston naming test*, *Wisconsin Card Sorting Test*, *Letter-Number* (subtest of the *Wechsler Adult Intelligent Scale III*) and *Digit Span* ([Table 3](#t3){ref-type="table"}).

###### Diagnostic protocol applied in studies selected.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                             Oscanoa\     Custodio\   Custodio\             Herrera-Pérez\        Custodio\    Custodio\             Oscanoa\    Custodio\             Custodio\             Custodio\
                                                             2004         2011        2012                  2013                  2014         2015                  2016        2016 \[A\]            2016 \[B\]            2017
  ---------------------------------------------------------- ------------ ----------- --------------------- --------------------- ------------ --------------------- ----------- --------------------- --------------------- ---------------------
  **Ruling out causes of secondary cognitive deficits**                                                                                                                                                                      

  • Depression                                               GDS ≤11      NR          BDI ≥13               BDI ≥ 13              NR           BDI ≥13               NR          BDI≥ 13               BDI≥ 13               BDI ≥ 13

  • Delirium                                                 ✓            NR          NR                    NR                    NR           NR                    NR          NR                    NR                    NR

  • Sensory disorder                                         ✓            NR          NR                    NR                    NR           NR                    NR          NR                    NR                    NR

  • Addiction/substance abuse                                NR           NR          ✓                     ✓                     ✓            ✓                     NR          ✓                     ✓                     NR

  • Use of medications that impair cognitive performance     NR           NR          NR                    NR                    NR           NR                    NR          NR                    NR                    ✓

  • Cerebrovascular pathology                                ✓            NR          ✓                     ✓                     ✓            ✓                     NR          ✓                     ✓                     ✓

  • Subdural hematoma                                        NR           NR          ✓                     ✓                     ✓            ✓                     NR          ✓                     ✓                     ✓

  • Severe TBI                                               NR           NR          ✓                     ✓                     ✓            ✓                     NR          ✓                     ✓                     ✓

  • Neuroinfections\*                                        NR           ✓           ✓                     ✓                     ✓            ✓                     NR          ✓                     ✓                     ✓

  • Vitamin B12 deficiency                                   NR           ✓           ✓                     ✓                     ✓            ✓                     NR          ✓                     ✓                     ✓

  • Hypothyroidism                                           NR           ✓           ✓                     ✓                     ✓            ✓                     NR          ✓                     ✓                     ✓

  • Liver disease                                            NR           NS          ✓                     ✓                     ✓            ✓                     NR          ✓                     ✓                     ✓

  • Chronic kidney disease                                   NR           ✓           ✓                     ✓                     ✓            ✓                     NR          ✓                     ✓                     ✓

  • Dementia of vascular origin                              NR           NA          HIS \> 4              HIS \> 4              HIS \> 4     HIS \> 4              NR          HIS \> 4              NR                    HIS \> 4

  • Laboratory tests                                         NR           ✓           ✓                     NS                    NR           ✓                     NR          ✓                     NS                    ✓

  • Imaging tests                                            CAT,\        NCCAT,\     CAT and/or MRI, all   CAT and/or MRI, all   NR           CAT and/or MRI, all   NR          CAT and/or MRI, all   CAT and/or MRI, all   CAT and/or MRI, all
                                                             all          all                                                                                                                                                

  Functional capacity assessments                            Katz ADL     PFAQ        PFAQ                  PFAQ                  PFAQ         PFAQ                  NR          PFAQ                  PFAQ                  PFAQ

  **Specialized neuropsychological assessment techniques**                                                                                                                                                                   

  • Medical                                                  Neurologic   NR          Neurologic            Neurologic            Neurologic   Neurologic            Geriatric   Neurologic            Neurologic            Neurologic

  • Neuropsychological                                       ✓            ✓           ✓                     ✓                     ✓            ✓                     ✓           ✓                     ✓                     ✓

  • Neuropsychological test battery                          NS           NR          ✓                     ✓                     NR           ✓                     NR          ✓                     ✓                     ✓

  • Executive function battery                               NR           NR          NR                    NR                    NR           ✓                     NR          NR                    NR                    NR

  • Neuropsychiatric assessment battery                      NR           NR          NPI                   NPI                   NR           NPI                   NR          NPI                   NR                    NR
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Regarding the diagnostic criteria applied in each of the studies, the DSM-IV and the *National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer\'s Disease and Related Disorders Association* (NINCDS-ADRDA) were the standards for diagnosing dementia and Alzheimer's disease. Similarly, we report the criteria utilized in a consistent manner for diagnosing other types of dementia. In this respect, the criteria utilized to classify the severity of the patients were the *Clinical Dementia Rating* (CDR), *Alzheimer's Disease Assessment Scale-cognitive subscale* (ADAS-cog), and the *Global Deterioration Scale* (GDS) ([Table 4](#t4){ref-type="table"}).

###### Diagnosis and severity criteria applied in studies selected.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                Oscanoa\        Custodio\            Custodio\       Herrera-Pérez\   Custodio\           Custodio\        Oscanoa\   Custodio\        Custodio\            Custodio\
                                2004            2011                 2012            2013             2014                2015             2016       2016 \[A\]       2016 \[B\]           2017
  ----------------------------- --------------- -------------------- --------------- ---------------- ------------------- ---------------- ---------- ---------------- -------------------- -------------------
  **Diagnostics**                                                                                                                                                                            

  • Dementia                    DSM-IV          NE                   DSM-IV          DSM-IV           NR                  DSM-IV           DSM-IV     DSM-IV           DSM-IV               DSM-IV

  • Mild cognitive impairment   NA              NA                   NA              AAN              Petersen Criteria   NA               NA         NA               NA                   Petersen Criteria

  • Alzheimer\'s disease        NINCDS-ADRDA    NINCDS-ADRDA         NINCDS-ADRDA    NINCDS-ADRDA     NINCDS-ADRDA        NA               NA         NINCDS-ADRDA     NINCDS-ADRDA         NINCDS-ADRDA

  • Vascular dementia           NA              NINDS-AIREN          NA              NA               NA                  NA               NA         NA               NINDS-AIREN          NA

  • Frontotemporal dementia     NA              Neary Criteria       Neary\          Neary\           NA                  Neary Criteria   NA         Neary Criteria   Neary Criteria       NA
                                                                     Criteria        Criteria                                                                                               

  • Lewy body dementia                          McKeith Consortium   NA              NA               NA                  NA               NA         NA               McKeith Consortium   NA

  • Parkinson\'s disease        NA              NA                   NA              UK-PDSBB         NA                  NA               NA         NA               NA                   NA

  **Severity**                                                                                                                                                                               

  • Criteria                    CDR             NR                   ADAScog         ADAScog          GDS                 CDR              GDS        CDR              CDR                  CDR

  • Results                     CDR 1: 32.3%\   NR                   ADAScog\        ADAScog\         GDS 4-5             CDR 0.5-1        GDS 3-5    NS               CDR 1: 39.8%\        NS
                                CDR 2: 38.7%\                        mild-moderate   mild-moderate                                                                     CDR 2: 34.9%\        
                                CDR 3: 29.0%                                                                                                                           CDR 3: 25.0%         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR: not reported; NS: reported, but not specified; NA: Not applicable; AAN: American Academy of Neurology for diagnosing mild cognitive impairment; ADAScog: Alzheimer\'s Disease Assessment Scale-cognitive subscale; CDR: Clinical Dementia Rating; Neary Criteria: Clinical consensus criteria for diagnosing frontotemporal dementia; Petersen Criteria: diagnostic criteria for mild cognitive impairment; DSM-IV: Diagnostic and Mental Statistical Manual of Disorders, 4^th^ edition; GDS: Global Deterioration Scale; McKeith Consortium: diagnostic criteria for dementia with Lewy bodies; NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer\'s Disease and Related Disorders Association; NINDS-AIREN: National Institute of Neurological Disorders and Stroke - Association Internationale pour la Recherche et l\'Enseignement en Neurosciences for diagnosing vascular dementia; and UK-PDSBB: United Kingdom Parkinson\'s Disease Society Brain Bank for diagnosing Parkinson\'s disease.

BCT performance analysis
------------------------

With regards to the BCTs evaluated, we observed that for discriminating between dementia and controls, the IFS (AUC: 0.99) and ACE (ABC: 0.95 to 1.00) showed superior performance to that observed by the FAB (AUC: 0.95), CDT-Mv (AUC: 0.94), and MMSE (AUC: 0.74 to 0.97). For discrimination between dementia of the Alzheimer type and controls, the M\@T (AUC: 1.00) and CDT-Mv (AUC: 0.94 to 1.00) showed superior performance to that observed for the MMSE (AUC: 0.72 to 1.00). For discriminating between FTD and controls, the IFS (AUC: 0.98) showed superior performance to that of the FAB (AUC: 0.73) ([Table 5](#t5){ref-type="table"}).

###### Psychometric properties of brief cognitive tests evaluated in studies selected.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                      Study\                                      Reference group                             Cut-off point                            AUC     Sensitivity (%)   Specificity (%)   Correctly\       LR+     LR-     PPV (%)   NPV (%)                                  Cronbach\'s alpha                        Pearson\'s coefficient
                                                                      group                                                                                                                                                                        classified (%)                                                                                                               
  -------------------------------------------- ---------------------- ------------------------------------------- ------------------------------------------- ---------------------------------------- ------- ----------------- ----------------- ---------------- ------- ------- --------- ---------------------------------------- ---------------------------------------- ----------------------------------------
  **ACE** ^[†](#TFN10){ref-type="table-fn"}^   Custodio, 2012         Dementia (AD+FTD)                           Control                                     86/100                                   1.000   100               100               NR               NR      NR      NR        NR                                       0.82                                     0.85^[‡](#TFN11){ref-type="table-fn"}^

  Herrera-Pérez, 2013                          Dementia               Depression                                  85/100                                      0.997                                    90.00   100               98.37             NR               NR      NR      NR        NR                                       NR                                       

  Dementia                                     Control                90/100                                      0.948                                       97.00                                    67.00   NR                NR                NR               NR      NR      NR        NR                                                                                

  **VLOM/ACE**                                 Custodio, 2012         FTD                                         AD+Control                                  2.84                                     NR      100               100               NR               NR      NR      NR        NR                                       NR                                       NR

  FTD+Control                                  AD                     4.92                                        NR                                          100                                      100     NR                NR                NR               NR      NR      NR        NR                                                                                

  **MMSE**                                     Custodio, 2011         Dementia                                    Control                                     25/30                                    0.972   100               85.40             92.70            6.87    0.00    NR        NR                                       NR                                       NR

  Herrera-Pérez, 2013                          Dementia               Depression                                  27/30                                       0.887                                    67      88.00             NR                NR               NR      NR      NR        NR                                       NR                                       

  Dementia                                     Control                28/30                                       0.895                                       97                                       67.00   NR                NR                NR               NR      NR      NR        NR                                                                                

  Custodio, 2014                               MCI                    Control                                     28/30                                       0.8456                                   83.89   68.89             80.89             NR               NR      NR      NR        NR                                       NR                                       

  DAT                                          Control                24/30                                       1.000                                       100                                      96.67   98.89             NR                NR               NR      NR      NR        NR                                                                                

  DAT                                          MCI                    24/30                                       1.000                                       100                                      96.67   97.78             NR                NR               NR      NR      NR        NR                                                                                

  Custodio, 2016 \[B\]                         Dementia               Control                                     ≥ 18^[‡](#TFN11){ref-type="table-fn"}^/30   0.74                                     64.10   84.10             NR                4.00             0.40    24.40   96.70     NR                                       NR                                       

  AD                                           Control                ≥ 18^[‡](#TFN11){ref-type="table-fn"}^/30   0.72                                        60.00                                    84.10   NR                3.80              0.50             23.20   96.30   NR        NR                                                                                

  Custodio, 2017                               MCI                    Control                                     21/30                                       0.6536                                   90.91   13.33             69.88             1.05             0.68    NR      NR        NR                                       NR                                       

  DAT                                          Control                21/30                                       0.8820                                      90.91                                    75.31   84.65             3.68              0.12             NR      NR      NR        NR                                                                                

  DAT                                          MCI                    21/30                                       0.8278                                      86.67                                    75.31   79.37             3.51              2.07             NR      NR      NR        NR                                                                                

  **CDT-Mv**                                   Oscanoa, 2004          AD                                          Control                                     6/10^[‡](#TFN11){ref-type="table-fn"}^   NR      83.90             93.50             NR               NR      NR      92.90     85.30                                    NR                                       NR

  Custodio, 2011                               Dementia               Control                                     7/10                                        0.9437                                   99.03   83.50             91.30             6.00             0.01    83.00   99.00     0.82                                     0.85^[‡](#TFN11){ref-type="table-fn"}^   

  Custodio, 2016 \[B\]                         Dementia               Control                                     7/10                                        0.94                                     89.30   98.10             NR                47.79            0.11    79.30   99.10     NR                                       NR                                       

  Custodio, 2016 \[B\]                         AD                     Control                                     7/10                                        0.94                                     90.00   98.10             NR                48.20            0.10    79.04   99.20     NR                                       NR                                       

  Custodio, 2017                               MCI                    Control                                     8/10                                        0.687                                    95.04   31.11             77.71             1.38             0.16    NR      NR        NR                                       NR                                       

  DAT                                          Control                5/10                                        1.000                                       100                                      87.65   95.05             8.10              0.00             NR      NR      NR        NR                                                                                

  DAT                                          MCI                    5/10                                        1.000                                       100                                      87.65   92.06             8.10              0.00             NR      NR      NR        NR                                                                                

  **FAB**                                      Custodio, 2016 \[A\]   Dementia\                                   Control                                     14.5/18                                  0.95    97.90             81.10             NR               NR      NR      NR        NR                                       NR                                       NR
                                                                      (AD+bvFTD)                                                                                                                                                                                                                                                                                                

  bvFTD                                        DAT                    13/18                                       0.73                                        82.30                                    48.5    NR                NR                NR               NR      NR      NR        NR                                                                                

  **IFS**                                      Custodio, 2015         FTD                                         NR                                          NR                                       NR      NR                NR                NR               NR      NR      NR        NR                                       NR                                       NR

  Custodio, 2016 \[A\]                         Dementia\              Control                                     23.5/30                                     0.99                                     97.10   97.90             NR                NR               NR      NR      NR        NR                                       NR                                       
                                               (AD+bvFTD)                                                                                                                                                                                                                                                                                                                       

  bvFTD                                        DAT                    17.5/30                                     0.98                                        94.12                                    94.20   NR                NR                NR               NR      NR      NR        NR                                                                                

  **M\@T**                                     Custodio, 2014         MCI                                         Control                                     37/50                                    0.999   98.33             97.78             98.22            NR      NR      NR        NR                                       NR                                       NR

  DAT                                          Control                27/50                                       1.00                                        100                                      98.89   99.63             NR                NR               NR      NR      NR        NR                                                                                

  DAT                                          MCI                    27/50                                       1.00                                        100                                      98.89   99.26             40.50             0.000            NR      NR      NR        NR                                                                                

  Custodio, 2017                               MCI                    Control                                     35/50                                       0.996                                    99.17   91.11             96.99             11.16            0.009   NR      NR        NR                                       NR                                       

  DAT                                          Control                29/50                                       1.000                                       100                                      98.77   99.50             81.00             0.00             NR      NR      NR        NR                                                                                

  DAT                                          MCI                    26/50                                       0.996                                       100                                      97.53   98.41             NR                NR               NR      NR      0.79      0.79^[‡](#TFN11){ref-type="table-fn"}^                                            

  **PMT**                                      Oscanoa, 2016          Dementia                                    Control                                     24/31                                    NR      90.50             83.30             NR               NR      NR      NR        NR                                       NR                                       NR
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACE: Addenbrooke\'s cognitive examination; AD: Alzheimer\'s disease; AUC: area under the ROC curve; bvFTD: behavioral variant frontotemporal dementia; CDT-Mv: clock drawing test, Manos version; DAT: dementia of the Alzheimer type; FAB: frontal assessment battery; FTD: frontotemporal dementia; PMT: Peruvian money test; IFS: INECO frontal screening test; LR+: positive likelihood ratio; LR-: negative likelihood ratio; M\@T: memory alteration test; MCI: mild cognitive impairment; MMSE: mini-mental state exam; NPV: negative predictive value; NR: not reported; PPV: positive predictive value; VLOM: verbal-language/orientation-memory ratio;

Peruvian version of ACE test, an adaptation of original version developed for Mathuranath and colleagues;

In relation to MMSE.

Comparing performance in discriminating between MCI and controls, the M\@T (AUC: 0.99) proved better than both the CDT-Mv (AUC: 0.69) and MMSE (AUC: 0.65 to 0.85). For discriminating between MCI and dementia of the Alzheimer type (DAT), the CDT-Mv (AUC: 1.00) and M\@T (ABC: 1.00) had better performance than the MMSE (AUC: 0.83 to 1.00). Finally, for discriminating between dementia and depression, the ACE (AUC: 1.00) performed better than the MMSE (AUC: 0.89) ([Table 5](#t5){ref-type="table"}).

DISCUSSION
==========

Implications
------------

This study assessed seven BCTs (the MMSE, ACE, CDT-Mv, FAB, IFS, M\@T, and the PMT). According to our results, the IFS, ACE, M\@T and CDT-Mv showed acceptable performance levels for the discrimination of various types of cognitive impairment. Likewise, a data comparison reported in a recently published systematic review[@B30] observed that the performance of the ACE in Peruvian samples was similar for the discrimination between DAT and controls (AUC: 0.98).

The majority of the BCTs included evaluate global cognitive efficiency (MMSE, ACE, CDT-Mv and PMT), which have a distinct value in LMICs such as Peru given that the prevalence of cognitive impairment of vascular origin and mixed dementia tends to be greater in these countries.[@B31] In turn, the remaining tests focus on evaluating executive functions (FAB and IFS), that better discriminate cases of FTD and vascular dementia or on memory function (M\@T) that best discriminate typical cases of DAT.[@B32]

The level of scientific evidence suggests that in Andean countries such as Peru, there is a lack of community-based studies. Of the total number of studies included, only one was conducted in a community setting, including persons with low levels of education. This represents a valuable opportunity to improve future studies in that diagnostic accuracy for BCTs varies in community and clinical settings.[@B33]

We evaluated for homogeneity with regard to key sociodemographic variables. Six out of 10 studies were heterogeneous for one of these variables, primarily age - which is considered a direct reflection of age and dementia prevalence.[@B34] We considered that the heterogeneity observed for other variables does not compromise validity in the studies given that sex is not a determinant of cognitive performance and that education effects can be adjusted for (in the case of CDT-Mv).[@B35] ^-^ [@B36]

It has been recommended that after a cognitive complaint suggesting the presence of dementia, a generalist should conduct a physical exam, request bloodwork and urine testing to rule out reversible causes for cognitive impairment, all in addition to applying a BCT. In countries like Canada[@B37] and Chile,[@B38] the primary care physician has a major role in diagnosing dementia. In the case of clinical specialists, their initial evaluation includes a neurologic evaluation and applying a BCT.[@B39] In this regard, it is fundamentally important to report the evidence available to help support decision-making in selecting a BCT.

The NICE guide, an international reference, considers a specific BCT set for the initial diagnostic evaluation of a patient suspected of having dementia that includes the *10-point Cognitive Screener* (10-CS), *6-item Cognitive Impairment Test* (6CIT), *6-item screener*, *Memory Impairment Screen* (MIS), Mini-Cog, and the *Test Your Memory* (TYM) assessment.[@B39] None of these tests have been evaluated in communities of Andean countries, probably due to the fact that they were not designed to be used in settings with zero to low levels of education in different cultural settings, such as is the case with Peru.

Even though there is limited evidence, data suggests that given the broad spectrum of global cognitive tests and their performance observed, the ACE can be a first line option in screening for cognitive impairment, particularly when the optimal time to administer the test is available (around 20 minutes).[@B40] ^,^ [@B41] Moreover, the M\@T can be a good option to confirm suspected cases of AD, whereas the IFS is suited for detecting FTD or vascular disease.[@B42]

The clinical utility of the BCTs needs to be analyzed in a rigorous manner. It is indeed a valuable tool for opportune identification of cognitive impairment in primary care settings. It is also important to rule out that obtaining normal results after conducting a BCT should not be considered the only input to rule out a diagnosis of dementia.[@B39] This is particularly important in individuals with high levels of education and a good cognitive reserve, or even in cases of recurring depression where a complete neuropsychological evaluation and longitudinal follow-up tend to be clues for establishing a diagnostic.

Limitations
-----------

Akin to all systematic investigations, we faced the challenge of a lack of data in the original studies available.[@B30] Consequently, we cannot rely on the validity of the results for rural populations or populations whose native language is not Spanish, since original studies did not include these populations. Additionally, the studies selected did not report data about the reliability (inter-observer and test-retest) and practicality (training demand, administration time, implementation costs) of the tests assessed. Finally, another means of improvement relates to the uniformity of the data reported, since none of the studies covered all the information required for this systematic mapping (see tables).

Strengths
---------

A recently published systematic review addressed the BCT topic for cognitive impairment,[@B30] ^,^ [@B33] but does not comprise publications conducted in the Spanish language or indexed in databases such as LILACS. Another distinguishing point in our study is the performance mapping of a BCT set in different subtypes of dementia. Another strength is in reference to the inclusion criteria and detailed evaluation of the rates of diagnostic accuracy, an observation made in other publications.[@B30] ^,^ [@B43]

Conclusions
-----------

Our investigation further supports evidence for the IFS, ACE, M\@T and CDT-Mv as viable options for discriminating various types of cognitive decline and identified the ACE as potentially the best alternative screening test evaluating global cognitive impairment. However, more reliable studies are needed that incorporate the diversity of the local setting in Andean countries to provide sound recommendations.

Recommendations
---------------

We stress that there is no assessed BCT providing optimal diagnostic performance to discriminate between the different forms of cognitive impairment. Therefore, primary care physicians should focus on the strategies of selection and prioritization of the BCTs based on their clinical suspicions. Considering the available data, in the Peruvian setting we recommend starting with the ACE whenever possible, subsequently opting for the M\@T and IFS in cases of suspected AD or FTD, respectively.

This first recommendation is particularly valid for urban contexts in Peru. For environments outside the Peruvian context, its validity depends on the similarity in sociodemographic conditions. Thus, according to previous reports, we anticipate better validity for Andean countries and Mexico.[@B44] ^,^ [@B45] Additionally, further investigation on this topic is necessary, particularly for adapting, validating and assessing the several BCTs in each region.[@B46]

Taking into account the Latin-American context, future investigations should collect data on subjects with different levels of education (including low- educated and illiterate individuals), geographical location (including rural zones),[@B47] and mother tongue (including indigenous languages),[@B43] as well as report all data about the psychometric properties of BCTs (performance, reliability and practicality). Our study could be used as the basis for generating a checklist for research protocols.

In settings with limited resources for the administration and scoring of BCTs, it is recommended to have digital assessment tools in place that can be self-administered.[@B43] Unfortunately, none of the studies included had applied BCTs with these characteristics. Given their greater usability potential for population-based screening, it is necessary to evaluate the performance of computerized BCTs, such as the *Computer Assessment of Mild Cognitive Impairment* or the UCSF Brain Health Assessment, as well as those that are not yet computerized may be administered with the use of information technology such as the IFS, ACE, or the M\@T.

This study was conducted at the Unidad de investigación de deterioro cognitivo y prevención de demencia, Instituto Peruano de Neurociencias. Lima, Perú.
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